Matthias Drosten

List of Publications by Year
in descending order

19 papers	1,394 citations	759233 12 h-index	839539 18 g-index
19 all docs	19 docs citations	19 times ranked	2855 citing authors

#	Article	IF	Citations
1	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature, 2017, 548, 234-238.	27.8	394
2	Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO Journal, 2010, 29, 1091-1104.	7.8	267
3	Targeting the MAPK Pathway in KRAS-Driven Tumors. Cancer Cell, 2020, 37, 543-550.	16.8	253
4	Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras. Molecular Cell, 2011, 44, 893-906.	9.7	127
5	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discovery, 2018, 8, 648-661.	9.4	97
6	A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. PLoS Genetics, 2017, 13, e1006622.	3.5	45
7	Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. Genes and Development, 2017, 31, 1456-1468.	5.9	41
8	The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle, 2018, 17, 702-711.	2.6	36
9	Ras signaling is essential for skin development. Oncogene, 2014, 33, 2857-2865.	5.9	34
10	Targeting KRAS mutant lung cancer: light at the end of the tunnel. Molecular Oncology, 2022, 16, 1057-1071.	4.6	23
11	Requirement for epithelial p38Î± in KRAS-driven lung tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2588-2596.	7.1	16
12	Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24415-24426.	7.1	15
13	Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets. Journal of Molecular Medicine, 2016, 94, 121-135.	3.9	12
14	KSR induces RASâ€independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. Molecular Oncology, 2022, 16, 3066-3081.	4.6	10
15	KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	9
16	Genetic analysis of Ras genes in epidermal development and tumorigenesis. Small GTPases, 2013, 4, 236-241.	1.6	8
17	Genetic Validation of Cell Proliferation via Ras-Independent Activation of the Raf/Mek/Erk Pathway. Methods in Molecular Biology, 2017, 1487, 269-276.	0.9	5
18	Ras and p53: An unsuspected liaison. Molecular and Cellular Oncology, 2016, 3, e996001.	0.7	2

#	Article	IF	Citations
19	Ras in epidermal proliferation. Oncotarget, 2014, 5, 5194-5195.	1.8	0